Trials / Terminated
TerminatedNCT03339999
AGN-242428 in the Treatment of Plaque Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AGN-242428 in Patients With Plaque Psoriasis
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Vitae Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of 3 doses of AGN-242428 in adult participants with moderate to severe plaque-type psoriasis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AGN-242428 | AGN-242428 administered as an oral capsule(s) once daily. |
| DRUG | Placebo | Placebo administered as an oral capsule(s) once daily. |
Timeline
- Start date
- 2017-11-15
- Primary completion
- 2018-03-22
- Completion
- 2018-04-20
- First posted
- 2017-11-13
- Last updated
- 2021-04-06
- Results posted
- 2021-04-06
Locations
15 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03339999. Inclusion in this directory is not an endorsement.